Can Samsung Bioepis reshape Europe’s retinal disease biosimilar market with OPUVIZ?

Find out how Samsung Bioepis’ OPUVIZ launch could reshape Europe’s aflibercept biosimilar market and ophthalmology access.

Find out how Samsung Bioepis’ OPUVIZ launch could reshape Europe’s aflibercept biosimilar market and ophthalmology access.

ECMO transport is a clinical weak point. Medtronic’s VitalFlow CE mark tests whether device mobility can strengthen critical care networks.

Read how Novo Nordisk may be reducing one of the biggest GLP-1 delivery barriers in Europe and what it could mean for Wegovy’s market expansion.